626
Participants
Start Date
January 31, 2012
Primary Completion Date
April 30, 2015
Study Completion Date
April 30, 2015
Anifrolumab 300 mg
Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
Anifrolumab 1000 mg
Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
Placebo
Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
Research Site, Birmingham
Research Site, La Jolla
Research Site, La Palma
Research Site, Long Beach
Research Site, Los Angeles
Research Site, Palm Desert
Research Site, San Leandro
Research Site, Upland
Research Site, Miami
Research Site, Ocala
Research Site, Orlando
Research Site, Palm Harbor
Research Site, Tampa
Research Site, Atlanta
Research Site, Decatur
Research Site, Stockbridge
Research Site, Idaho Falls
Research Site, Chicago
Research Site, Indianapolis
Research Site, Las Cruces
Research Site, New York
Research Site, Charlotte
Research Site, Raleigh
Research Site, Columbus
Research Site, Edmond
Research Site, Tulsa
Research Site, Memphis
Research Site, Houston
Research Site, Seattle
Research Site, Spokane
Research Site, Rio de Janeiro
Research Site, São Paulo
Research Site, Plovdiv
Research Site, Sofia
Research Site, Barranquilla
Research Site, Bogotá
Research Site, Bucaramanga
Research Site, Chía
Research Site, Medellín
Research Site, Brno
Research Site, Prague
Research Site, Uherské Hradiště
Research Site, Budapest
Research Site, Debrecen
Research Site, Dantoli-Nagpur
Research Site, Hyderabad
Research Site, Mumbai
Research Site, New Delhi
Research Site, Pune
Research Site, Secunderabad
Research Site, Guadalajara
Research Site, León
Research Site, México
Research Site, Toluca
Research Site, Arequipa
Research Site, Lima
Research Site, Bialystok
Research Site, Bydgoszcz
Research Site, Krakow
Research Site, Nadarzyn
Research Site, Poznan
Research Site, Brasov
Research Site, Iași
Research Site, Târgu Mureş
Research Site, Gwangjin-gu
Research Site, Gwangju
Research Site, Seodaemun-gu
Research Site, Suwon
Research Site, Chiayi City
Research Site, Kaohsiung City
Research Site, Taichung
Research Site, Taipei
Research Site, Donetsk
Research Site, Kyiv
Research Site, Luhansk
Research Site, Lviv
Research Site, Ternopil
Research Site, Vinnitsya
Research Site, Vinnytsia
Lead Sponsor
MedImmune LLC
INDUSTRY